The SGLT2 Inhibitor Dapagliflozin Improves Prognosis in Systolic Heart Failure Independent of the Obesity Paradox
2016 ◽
Vol 18
(5)
◽
pp. 545-553
◽
Keyword(s):
2012 ◽
Vol 110
(1)
◽
pp. 77-82
◽
2015 ◽
Vol 115
(2)
◽
pp. 209-213
◽
2011 ◽
Vol 57
(14)
◽
pp. E198
2003 ◽
Vol 91
(7)
◽
pp. 891-894
◽
Keyword(s):
Keyword(s):
2011 ◽
Vol 17
(5)
◽
pp. 374-380
◽
Keyword(s):